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Abstract 
 
HCN gene modified Human Mesenchymal Stem Cells (hMSCs) have shown the ability to 
restore pacemaker function in canine and murine models. However, stem cell migration from the 
delivery site is a major concern. To address this problem, the team designed a device to prevent 
migration but still allow communication between the stem cells and native cardiomyocytes. 
Scaffold pore size, fiber diameter and biomaterial selection were necessary to determine. The 
team conducted a pore size migration assay, cell deflection calculations, gap junction formation 
assay and cell viability assays. The results from the tests led to the design of a two part 
polyurethane scaffold that prevents migration of stem cells, allows gap junction formation 
through pores and is packaged for minimally invasive delivery.  
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Chapter 1: Introduction 
Significance  
 
Electronic pacemakers are readily available devices that are used to solve a variety of 
heart problems, extending from simple heart rate and rhythm problems to complete heart failure 
(Rosen et al. 2004). Even though these devices are proven to be effective, they still have a 
variety of limitations. Among these limitations include the pacemaker’s battery life, sensitivity to 
magnetic fields, and lead failure. These drawbacks require that a patient undergo repeated 
operations to replace the battery; they also inhibit the patient’s ability to undergo other tests such 
as MRIs and CT Scans. Furthermore, there are also complications related to the implantation of 
the pacemaker. For instance, if the pacemaker leads are improperly placed, it can cause the 
wrong parts of the heart to contract, resulting in inefficient pumping and in severe cases, death 
(Rosen et al. 2004). Perhaps the greatest disadvantage associated with the electrical pacemaker is 
that it lacks the ability to provide an appropriate cardiac response when the patient is exercising 
or is experiencing a strong emotional reaction (Rosen et al. 2004).  
Biological pacemakers are being developed as an alternative to these electrical 
pacemakers with the hope of mimicking the natural pacemaker and overcoming some of the 
electronic pacemaker’s limitations. By utilizing stem cells as a biological pacemaker, they will 
be capable of providing an appropriate cardiac response to exercise and emotions since the cells 
can react to the physiological changes in the body (Rosen et al. 2004). Also, these biological 
pacemakers do not contain batteries or leads; therefore the device is not sensitive to magnetic 
fields. This would provide the patient with a better alternative to cure their heart condition. 
Although stem cells have good qualities that allow them to be ideal for engineering 
biological pacemakers, there are some risks associated with them. One of the biggest risks is 
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stem cell migration. If these undifferentiated cells were to migrate to other areas of the heart, 
they could cause problems like fibrillation, beating of non-cardiac muscle tissue, or cancer 
(Rosen et al. 2004). To address this problem, the team researched a method of containing the 
stem cells to prevent migration while still allowing communication between the stem cells and 
the surrounding cardiomyocytes. 
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Chapter 2: Literature Review 
 
The heart is one of the most vital organs in the human body. There are a variety of 
cardiac diseases and conditions that result in over 700,000 deaths per year (29% of total), making 
cardiac disease the leading cause of death in the United States (CDC Website, 2008). 
The Heart  
Structure 
 
The heart is located just posterior of the ribcage, anatomically left of the sternum. The 
heart wall has three layers (see Figure 1). The outermost layer is the epicardium, which serves as 
a protective layer for the heart. Beneath the epicardium is the myocardium, where the bulk of the 
heart’s mass is located; it is responsible for the majority of the contractile force when the heart 
beats. Lastly, the endocardium is composed of endothelial muscle cells, which are held together 
by connective tissue fibers called bundles (Marieb & Hoehn, 2007).  
 
 
 
Figure 1: Layers of the Heart Wall (Mayo Foundation) 
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The heart is divided into four chambers and connected to several major blood vessels (see 
Figure 3). As deoxygenated blood enters the heart, it follows a specific path through these 
chambers and vessels prior to re-circulating through the body. The process begins when the vena 
cava empties deoxygenated blood into the right atrium. The blood then goes through the 
tricuspid valve into the right ventricle, where the heart contracts and pumps blood through the 
pulmonary valve into the pulmonary artery. This blood is then oxygenated at the lungs and 
brought back to the left atrium of the heart via the pulmonary veins. After a contraction, the 
mitral valve opens and blood empties into the left ventricle. The heart contracts again and the left 
ventricle pumps the newly oxygenated blood through the aortic valve into the aorta, where it 
circulates to the rest of the body.  
The responsibility of the valves that separate the different chambers of the heart is to 
prevent back flow. When the heart contracts, the aortic and pulmonary valves open, while the 
mitral and tricuspid valves close (see Figure 2). When the heart relaxes, the opposite occurs. The 
cardiac cycle has two parts, which correspond to ventricular contraction and relaxation: the peak 
systolic pressure occurs during the heart’s contraction, while diastolic pressure occurs during 
relaxation. Normal human blood pressure is 120 systolic pressure over 80 diastolic pressure 
(Fox, 2008).  
 
  
 
Figure 2: Chambers and Valves of the Heart (Mayo Foundation) 
11 
 
The heart is composed of muscle fibers which are similar to those of skeletal and smooth 
muscle, yet they are fundamentally different in a couple ways. Much like skeletal muscle, 
cardiac muscle is striated and contracts by sliding filaments. The difference, however, exists in 
their structure: cardiac muscle fibers are shorter, branched, and connected to each other.  
On the cellular level, each cardiac muscle cell’s plasma membrane is connected to other 
cells by an intercalated disk. Within this disk there are desmosomes, which act to hold the 
muscle cell together as contraction occurs (Marieb & Hoehn, 2007). In order to ensure efficient 
communication between adjacent cardiomyocites, gap junctions connect the cells. These gap 
junctions serve as passageways for the flow of ions, which is how an electrical current gets 
propagated throughout the entire heart. Gap junctions are essential in the proper pacing of the 
heart. While various skeletal fibers have individual innervations, heart cells act together as a 
single unit to efficiently pump blood. 
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Mechanical Function 
 
The human heart beats approximately 72 times per minute (76 to 80 for adult females; 72 
for males; and 50-65 for elderly), with an average of 100,000 times per day. An average adult 
has about five liters circulating through their body at any moment, which equals approximately 
2,000 gallons of blood being pumped by the heart every day. To put this into perspective, a 
seventy year old human’s heart has beaten more than 2.5 billion times and has pumped more 
than 1 million barrels of blood (Bronzino, 2006). However, this is dependent upon a person’s 
blood pressure, which is the force exerted by circulating blood on the walls of blood vessels. An 
average range of normal blood pressure is 110 to 150mmHg over 60 to 80mmHg; the higher 
number (peak systolic pressure) is representative of the heart as it beats and the lower number 
(end diastolic pressure) describes the heart as it relaxes. 
An increase or decrease in blood pressure could significantly alter a person’s heart 
condition. In a study performed by William Grossman et al., the left ventricular (LV) wall 
stresses were measured throughout the cardiac cycle during cardiac catheterization of thirty 
patients; six patients had LV pressure overload, eighteen had LV volume overload, and six 
patients were used as a control group since they had no evidence of heart disease. The results of 
this study are shown in Figure 3.  
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Figure 3: Comparison of changes in LV pressure, wall thickness, and meridional stress throughout the cardiac cycle  
(Grossman et al., 1975) 
 
The normal peak systolic and end diastolic pressure were 117±7/10±1mmHg; patients 
with LV pressure overload had a great increase in pressure with readings of 220±6/23±3mmHg. 
Although not as significant as patients with LV pressure overload, patients with LV volume 
overload also showed an increase in pressure: 139±7/24±2mmHg. The meridional wall stress did 
not change dramatically between patients with no cardiac abnormalities and patients with 
pressure overload (151±14/17±2*10
3 
dyn/cm
2
 compared to 161±24/23±3*10
3
 dyn/cm
2
, 
respectively). This was due to the fact that the pressure overload was counterbalanced by an 
increase in the wall thickness (1.5±0.1cm for pressure overload compared to 0.8±0.1cm for 
normal heart conditions). For patients with volume overload, the peak systolic meridional wall 
stress (175±7dym/cm
2
) was slightly higher than normal heart, but was not too significant. There 
was a considerable increase in its end diastole wall stress, 41±3*10
3
 dyn/cm
2
 (Grossman, 
William et al., 1975). 
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Electrical Function 
 
The heart functions with the conduction of an electrical signal through the tissue to 
generate a contraction. A majority of the heart’s cells work just like any other muscle or nerve 
cell, they remain at a constant resting potential until stimulated by an outside source. These cells, 
which make up roughly 99% of the heart, carry out the mechanical functions the heart 
(Sherwood, 2004). 
Figure 4 depicts the typical cardiac potential of myocytes within the ventricle. Phase 4 is 
the resting potential of the cardiac cell, and it remains in this state until excited by a neighboring 
cell. The cell maintains this negative membrane potential partly because of the ik1 (termed the 
inwardly rectifying K
+
) current, which has the K
+
 ions flowing outside of the cell membrane, 
where the concentration of K
+
 ions is lower (Levy, 2007). Despite a higher concentration of Na
+
 
ions on the outside of the cell, the cell membrane is not very permeable to Na
+
 ions. However, 
when the fast Na
+
 channels are opened, Phase 0 occurs (Levy, 2007). Referred to as the rapid 
depolarization phase, this stage occurs when Na
+
 channels open up, allowing a quick influx of 
positive Na
+
 ions into the cell, causing the cell to fire an action potential (Sherwood, 2004). 
 
 
 
Figure 4: Myocyte Action Potential (Klabunde, 2007) 
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Phase 1 occurs when these Na
+
 channels are all closed, and K
+
 ions begin to flow outside 
of the cell, partially re-polarizing it (Levy, 2007). This small deflection is counteracted in Phase 
2 when there is steady influx of Ca
+2
 ions, and the outflow of K
+
 ions continues (Levy, 2007). 
Finally, the sharp decline of Phase 3 occurs when the Ca
+2
 channels close while the K
+
 channels 
are still open (Levy, 2007). This outward current causes the cell to repolarize. The K
+
 channels 
only close once the cell has reached its resting potential of around -80mV (Levy, 2007). 
The other 1% of heart cells are unique in that they can generate and conduct their own 
action potentials (Sherwood, 2004). These cells, termed autorhythmic cells, are what drive the 
natural beating of the heart. Affected by the sympathetic and parasympathetic nervous system, 
these cells generate action potentials based on the how quickly blood needs to be pumped 
through the rest of the body (Sherwood, 2004). These autorhythmic cells also have extended 
refractory periods to prevent summated action potentials, which allow ample time for the 
chambers to empty and fill (Levy, 2007). 
Autorhythmic cells do not have a resting potential like other cells; these cells slowly 
depolarize after an action potential has occurred and do not fire again until the threshold 
potential is reached (Sherwood, 2004). This behavior of repeated firing without an outside 
stimulus generates the natural pacemaker activity of the heart.  
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Figure 5: Pacemaker Electric Potential (Klabunde, 2007) 
  
This autorhythmic pacemaker activity is generated by a similar controlled flow of several 
important ions (see Figure 5). First, the autorhythmic cells reduce the amount of K
+
 ions that 
flow out, while constantly allowing Na
+
 in (Sherwood, 2004). These paired actions slowly 
depolarize the cell, bringing it closer to its firing threshold (in Figure 5, this is shown by if). Once 
these actions have begun and the cell is close to reaching the threshold, voltage gated Ca
+2 
channels open; this allows an influx of ions, which raises the cell potential to the threshold 
(Sherwood, 2004). These Ca
+2 
channels (T-Type and L-Type) are voltage gated and only begin 
working once the if has significantly raised the potential (Levy, 2007). Once the cell has reached 
its threshold, the rising phase of the action potential begins (Phase 0), followed by a quick efflux 
of K
+
 ions (Sherwood, 2004). This quick efflux of K
+
 ions, which is the same inwardly rectifying 
K
+
 current mentioned above, is shown in the above figure as ik. This marks the cell returning to 
its resting potential (Phase 3).  
This electrical activity happens in very specific parts of heart, which help create efficient 
pumping of the heart. In healthy hearts, this pacemaker activity commences at the SA node. The 
SA node, which is located in the right atrial wall near where the superior vena cava is connected 
17 
 
to the heart, is the primary pacemaker for heart function (Sherwood, 2004). The SA node is 
composed of two different kinds of cells: small, round cells and slender, elongated cells which 
initiate the current (Levy, 2007). The SA node fires an action potential roughly 70 to 80 times 
per minute (Sherwood, 2004). This action potential is first relayed via the four interatrial 
pathways at speeds of over 1 m/s to all of the contractile cells in both the right and left atrium 
(Levy, 2007).  That signal is then propagated through the internodal pathway until it reaches the 
AV node, where it is delayed for roughly 100ms; this small delay allows for the blood in the atria 
to empty into the ventricles (Sherwood, 2004).  
The AV node, often referred to as a latent pacemaker or a secondary pacemaker, is 
located at the base of the right atrium, alongside the dividing septum (Sherwood, 2004). The AV 
node is dubbed the secondary pacemaker because it only generates action potentials at a rate of 
40 to 60 times per minute (Sherwood, 2004). Because it is connected via gap junctions to the SA 
node, which fires more quickly, the AV node must relay action potentials at the same rate to 
ensure efficient pumping and filling. The AV node has three different areas: AN, N, and NH 
zones (Levy, 2007). The AN and N regions are similar in that they both serve to help delay the 
propagation of the electrical signal; this helps to ensure that the atria can completely empty prior 
to the ventricles contracting (Levy, 2007). The NH region is the transitional area between the AV 
into the Bundle of His; here the action potentials transfer back from slow response (which causes 
the delay in the AN/N portions) to fast response (Levy, 2007). 
From the AV node, the electrical signal is conducted down through the Bundle of His, 
which starts at the AV node and travels through the septum. In the septum, the Bundle of His 
breaks off into a left and right branch which travels around the base of the ventricles and up back 
towards the atria (see Figure 6). From here, the electrical signal is passed through the Purkinje 
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Fibers which wrap around the ventricles, thus completing the relay of the electrical signal 
(Sherwood, 2004). Much like the AV node, the Bundle of His and the Purkinje Fibers fire at a 
much slower rate than the SA node (around 20-40 action potentials per minute) (Sherwood, 
2004). However, since the SA node is firing at a more rapid rate, both the Bundle of His and 
Purkinje Fibers assume the same rate as the SA node to help generate a smooth contraction. 
During contraction, the first part of the ventricles to contract is the myocytes near the 
intraventricular septum (Levy, 2007). After these cells have contracted, the signal has caused the 
endocardial and epicardial cells to contract (Levy, 2007). This contractile flow helps to ensure 
that all the blood is efficiently pushed out of the ventricles into the arteries. 
 
 
 
Figure 6: Pathway of Electrical Propagation (Oregon Health & Science University, 2008) 
 
One major health issue with hearts is that the SA node can malfunction, or the connection 
between the SA node and AV node can become blocked. This leads to an interruption of the 
normal pacemaker activity. Instead of the heart beating at the rate of the SA node (about 70 times 
per minute), the heart is now firing at the rate of the AV node. Even though the heart is 
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functioning off the AV node, a slower beat results in the person feeling tired and unable to 
perform physical activity, along with other limitations in their natural activity. 
Another potential problem with the electrical activity of the heart is when a certain group 
of cells becomes hyperactive. This group of cells, called an ectopic focus, fire action potentials 
more rapidly than the SA node (Sherwood, 2004). This can lead to irregular and premature beats 
of the heart, which can result in inefficient pumping of blood. 
Arrhythmia 
One specific form of cardiac disease is arrhythmia. Arrhythmia is clinically diagnosed 
when there is a loss of contractile function of the heart, which can be caused by an 
atrioventricular (AV) block in the Bundle of His. This results in electrical impulses traveling too 
fast (bradycardia), too slow (tachycardia), or erratically (fibrillation) causing the blood pressure 
to become altered. If the blood pressure becomes too low, the arterial blood flow does not 
provide for the adequate perfusion to regions of the myocardium (Katz, 1977). Figure 7 
represents ECG tracings for a single cardiac cycle from a normal heart (shown on the left) and an 
abnormal heart (shown on the right). In a normal heart, the T wave is clearly distinct from the 
other waves in the ECG; also, the repolarization of the QRS wave does not go below that of the 
depolarization. However, in the ECG of an abnormal heart, there is no distinct T wave; instead 
there is a prolonged QT interval (the time between initial depolarization and final repolarization 
of the ventricles) and the repolarization of the ventricles goes below that of the depolarization.     
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Figure 7: Normal vs. Abnormal ECG Tracings  
(Sanguinette and Tristani-Firouzi, 2006) 
 
If cardiac diseases, such as arrhythmia, are not treated, they can become life-threatening 
and result in cardiac arrest and sudden death. A current treatment for arrhythmia is the 
implantation of an artificial electrical pacemaker. These pacemakers can restore the ventricular 
rate when the AV block is not too severe in order to prevent death in case the AV conduction 
was to suddenly fail.  
Artificial Pacemakers 
Pacemakers can either be permanent or temporary.  Temporary pacemakers are mainly 
used for severe cases of heart failure, such as a symptomatic bradycardia or tachycardia, or post 
cardiac surgery. These are used temporarily until further action, such as a surgical procedure to 
implant a permanent pacemaker, is taken. When the permanent pacemaker is used, it is 
implanted in a patient’s chest. The artificial pacemaker contains one or two electrodes that come 
into contact with the heart’s muscle fibers; the stimulating electrode is known as the cathode, and 
the other electrode, the anode, is placed in some distant area of the body. Pacemakers with a 
single electrode only stimulate the upper chambers of the heart; pacemakers with two electrodes 
stimulate both the upper and lower chambers of the heart. The latter pacemaker is able to be 
more precise in mimicking the heart rhythm (Elhendy, et al., 2008).   
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There are a couple of methods previously used in which the connecting wires could be 
brought to the heart. One method used a needle that was inserted through the chest wall into the 
heart, and then the electrodes were threaded through the needle. Another method used was 
stitching the wires into the heart muscle. The most recent method is to have the electrodes pass 
through the veins via a catheter and into the chambers of the heart so that there is contact with 
the inner surface of the right ventricle (Elhendy, et al., 2008). 
Parts to a pacemaker 
There are three distinct parts to a pacemaker: a generator, leads, and electrodes (see 
Figure 8).   
 
 
 
Figure 8: Parts of a Pacemaker (Heartonline, 2007) 
The generator, which is responsible for generating the electric impulses that correct the 
irregular heartbeat, is a small box that is on average 2 inches wide and weighs approximately 3 
ounces; however, they can be slightly larger or smaller. This part of the pacemaker is battery-
powered, and most use lithium batteries that last for 5 to 10 years. After the battery runs out, the 
entire generator has to be replaced. Extruding from the generator are the leads that are typically 
composed of platinum and have an insulating coating of silicone or polyurethane. The leads’ 
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function is to carry the electrical impulses from the generator to the electrodes, which are located 
at the tip of each lead. The purpose of the electrodes is to deliver the necessary electrical 
impulses to the heart.  
Types of artificial pacemakers 
A major concern for using artificial pacemakers is that the heart’s normal impulse is 
disturbed and offset by the artificial pacemaker, especially during the apex of the T wave. If this 
ensues, ventricular fibrillation will most likely occur. As a consequence, the “synchronous 
pacemaker” is most often used. This type of pacemaker is able to sense the atrial excitation 
wave, have an appropriate delay (approximately equal to a normal PR interval), and then 
stimulate the ventricles.  
The “standby pacemaker” is also often used because it can turn itself off when the heart 
does not need it. This pacemaker can sense the ventricular R wave when it occurs faster than the 
built-in, fixed rate of the pacemaker or when the R wave signals the pacemaker to fire without 
delay. In the former case, the pacemaker will block the next electrical stimulus; in the latter case, 
the electrical stimulus follows the refractory period of the R wave.  
The most recent artificial pacemakers are externally programmable, which allows the 
cardiologist to be able to select specific pacing modes for individual patients. Some of these 
pacemakers have multiple electrodes that stimulate different areas of the heart to maintain the 
heart’s normal pulse. Another recent pacemaker used is the biventricular pacemaker: a triple-lead 
pacemaker that simultaneously stimulates both ventricles of the heart in addition to pacing the 
right atrium. Most of these recent pacemakers incorporate a built-in device that shocks the heart 
back into a normal rhythm if it were to stop or if there was a serious rhythm abnormality. If a 
pacemaker uses this feature, it was called an implantable cardioverter defibrillator. 
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Human Mesenchymal Stem Cell (hMSC) Driven Biological Pacemaker 
In order to overcome the mentioned limitations of artificial pacemakers, the possibility of 
using biological pacemakers is being explored. Within these biological pacemakers are 
mesenchymal stem cells, which are multipotent stem cells that have the ability to differentiate 
into multiple cell lines like muscle, bone, cartilage, and tendon cells. Although these cells are 
available in different parts of the body, the most common place where these cells are obtained 
from is bone marrow (Rosen et al., 2004). This cell’s ability to differentiate into multiple cell 
lines makes it attractive for different kinds of cell therapies. Another advantage of mesenchymal 
stem cells is that they can be extracted from the patient’s own bone marrow, so therapies 
involving hMSCs will be autologous, reducing the risk of an immune response (Rosen et al., 
2004). 
Researchers are studying adult mesenchymal stem cells as a possibility for providing an 
off the shelf cell therapy because of the body’s low immune reaction to the stem cells. This is 
referred to as allogeneic stem cell transplantation. Due to the cells’ ability to transfer dye and to 
transmit current to other cells (not only within the same cell line, but also to other cell lines like 
cardiomyocytes), scientists are also researching the possibility of using adult mesenchymal stem 
cells as a vessel to deliver genes as well as small molecules (Rosen et al., 2004).  
After acknowledging these potential uses for adult mesenchymal stem cells, Rosen and 
his colleagues decided to explore the cells’ gene therapy possibilities and take it one step further. 
Their idea was to create a biological pacemaker by using adult mesenchymal stem cells that had 
been modified with the appropriate genes.  
In a normal pacemaker cell, the cell’s own depolarization initiates an action potential in 
the cell. This action potential is then transmitted to other cells via gap junctions, passing down 
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the current. For adult mesenchymal stem cells to mimic this natural depolarization, the cells 
would have to be modified in order to express an HCN isoform (Rosen et al., 2004). The HCN 
(Hyperpolarization-activated cyclic nucleotide gated) channels open in response to 
depolarization after an action potential. The opening of these channels allows an influx of 
sodium ions which is the cause of the spontaneous repolarization seen in Figure 5. The sodium 
ions then flow to the adjacent myocytes through gap junctions as seen in Figure 9. This occurs 
until threshold for the myocyte action potential is reached. The action potential is propagated to 
other myocytes through the gap junction chain. This mechanism allows for the synchronization 
of the depolarization current to the diastolic current, creating an on/off switch for the current to 
fire (Rosen et al., 2004). In this case, both the stem cell and the adjacent cardiomyocyte would 
work as a pacemaker. The advantage of this method is that this approach does not need the stem 
cell to differentiate into a pacemaker cell in order to perform its function. 
 
 
Figure 9: Top Panel - Action Potential Current is Initiated Purely by Adjacent Myocytes; Bottom Panel - Adjacent 
Myocytes Initiating the Stem Cell’s Action Potential 
 
Although adult mesenchymal stem cells offer a great advantage to the field of medicine 
by providing the possibility of biological pacemakers, there are still some great concerns that 
need to be addressed before this process becomes viable. Concerns include duration of function 
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of the biological pacemaker in comparison to the electronic pacemaker, immunological response 
from the body leading to cell rejection, neoplasia, cancer, migration of the cells from the 
implanted site to other areas of the heart or the rest of the body, and stem cell differentiation into 
other types of cells (Rosen et al., 2004). 
Cell Delivery 
 Discussions with Professor Glenn Gaudette (Worcester Polytechnic Institute) in 2008 
yielded certain possibilities for delivering the modified hMSCs to the heart. One method 
discussed was an intravenous vector. This vector had limited transfection efficiency and little to 
no targeted delivery (Gaudette, 2008). Another method discussed was direct injection into the 
heart wall. While direct, this method’s limitations include blowback of delivery serum and little 
control over cell migration (Gaudette, 2008).  
Scaffolding 
If dissociated cells were to be injected into the body it would be nearly impossible to control 
the shape, size, and location of the implanted cells (Shimizu et al., 2002). In order to help control 
these factors, scientists use different types of scaffolds. These scaffolds work as a support frame 
for cells to attach to and grow (see Figure 10). In order to keep the cells alive, the scaffold must 
permit the diffusion of cell nutrients and other molecules important for proper cell function. In 
the case of an implant, the scaffolds can be used to not only deliver cells, but biochemical factors 
as well. Another advantage of scaffolds is their ability to manipulate cell behavior by applying a 
series of mechanical and biological stresses. The biggest challenge posed by the use of scaffolds 
is the lack of cell migration into the 3-D structure. This is a problem because in healthy 
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myocardial tissue, cells are considerably dense when compared to other tissue including cartilage 
and vascular tissue (Shimizu et al., 2002). 
 
  
Figure 10: Scanning Electron Micrograph of a Scaffold (Leor et al., 2000) 
 
Different materials can be used to create these scaffolds depending on the mechanical 
conditions having to be withstood. The main materials used for scaffolds containing cardiac cells 
can be synthetic or biological. Among the synthetics it is possible to find woven nylon (PET – 
also known as Dacron), polytetrafluoroethyline (ePTFE), poly(glycolic acid) (PGA), gelatin and 
alginate (Shimizu et al., 2002). On the other hand, biological materials like gluteraldehyde-cross-
linked biological membranes, bovine tissue, and collagen scaffolds are also used (Robinson et 
al., 2005). 
There are several different ways of synthesizing tissue engineering scaffolds. One process 
is nanofiber self-assembly. The main advantage of this method is that the biomaterials created 
with this method develop properties similar to those of natural extracellular matrix (ECM). This 
similarity allows the scaffold to be more biocompatible than other scaffolds, including those 
derived from animal tissue. (Ma et al, 2005) 
Another way that these scaffolds can be synthesized is by using textile technologies. This 
process is used when non-woven meshes of different polymers are desired (see Figure 11). These 
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have been used successfully in growing different types of cells. The drawback of this method is 
that it is hard to control pore size and level of porosity. (Ma et al, 2005) 
 
Figure 11: Non-woven mesh of PGA fibers (METU) 
 
Solvent casting and particulate leaching is an additional way of synthesizing scaffolds. 
This method allows tissue engineers to control the porosity of the scaffold providing a material 
with a regular pore pattern. The drawback is that there is a limit on how thick the scaffold can be. 
Solvent casting starts by mixing the desired polymer into an appropriate organic solution. The 
solution is then poured into a mold and some porogens are added to the mix. Porogens are 
particles like sodium chloride, saccharose, or gelatin that are added to the solution before it sets. 
When these particles are removed they will give the scaffold its desired porous properties, 
including the size and amount of pores found in the scaffold. Once the polymer has been casted, 
the solution is allowed to evaporate leaving the polymer scaffold with the porogens still 
embedded in it. In order to remove the porogens, the scaffold is submerged in a liquid that 
dissolves the particles. Another drawback of this process is if all the porogens are not completely 
removed from the material, then these particles can damage the cells that are implanted onto the 
scaffold (Ma, 2005).  
Scientists have tried to overcome the drawbacks of the solvent casting and particulate 
leaching process by creating new means of making these 3-D structures. To avoid the damage 
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caused by the porogens that were not properly dissolved, they have moved from solid porogens 
to gas porogens. This process called gas foaming starts by creating a disc shaped mold out of the 
preferred polymer by means of compression molding with heat. In order to make the material 
porous, the disc is placed into a chamber where CO2 at high pressures is pumped in. The discs 
remain inside for a couple of days and then the chamber is slowly decompressed back to 
atmospheric pressure. During their time in the chamber, the discs are allowed to absorb the CO2 
which create the desired porous 3-D matrix. Once all the CO2 is removed, the structure maintains 
its shape. Although this process solves the problem caused by not fully dissolved porogens, it 
still has some disadvantages. The main drawback of this process is that the heat used during the 
compression molding part of the scaffold formation limits the materials that can be utilized (Ma, 
2005). 
Another method of creating scaffolds is electrospinning, which uses high voltages in 
combination with distace from the material source to the base in order to produce a cross-linked 
mesh. It can produce polymer fibers of nanometer to micrometer size in diameter; Figure 12 
shows 1.0μm polyurethane fibers that were produced via electrospinning. In a study performed 
by Angelo Pedicini et al., the authors electrospun the polyurethane solution from a 1mL glass 
pipette with a capillary tip of approximately 1 mm inner diameter. A stainless steel electrode was 
placed in the polymer solution. These were then spun onto a grounded aluminum foil sheet 
(Angelo Pedicini et al., 2003).  
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Figure 12: Polyurethane Fibers Produced by Electrospinning  
(Angelo Pedicini et al., 2003) 
 
A possible method for producing a biomaterial with pores is one that was done by Ze 
Zhang et al. in their study. The authors prepared a 7% (w/v) polyurethane solution by dissolving 
polyurethane pellets in 1,4-dioxane. They used phase inversion and freeze-drying to prepare the 
polyurethane tubes in an external cooling fashion. A glass capillary was inserted into a glass tube 
to form a casting mold, and then the polyurethane solution was poured into the space between 
the two glass tubes. Various cooling treatments were used for the polyurethane solution to 
become a solid; pore size is dependent upon the cooling rate. To remove the solvent, the mold 
was freeze-dried. Once the polyurethane was removed, it was sterilized in 70% alcohol (Zhang 
et.al., 2003). Figure 13 shows the microporous structure of polyurethane by using this 
methodology. 
 
Figure 13: Microporous structure of polyurethane  
(Zhang et al., 2003) 
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Chapter 3: Project Strategy 
Client Statement 
 
The goal of this project is to design a scaffold that will hold stem cells which are to be used 
as a biological pacemaker for implantation into the heart. The scaffold, which will be implanted 
within the ventricular septum via a minimally invasive approach, will immobilize the cells and 
prevent them from spreading to other areas of the heart or body. The scaffold will contain pores 
large enough to allow the stem cells to form gap junctions with neighboring myocytes, but small 
enough that they keep the stem cells within the container. This design will not impede the 
formation of these gap junctions, which are necessary to propagate an electrical current through 
the heart. The scaffold should be permanent and durable enough to withstand the normal 
contractile forces that are associated with heart function. The scaffold will be placed adjacent to 
living cardiomyocytes, and therefore, should not impede the normal physiological functions of 
these cells. 
Functions 
 Immobilize cells – scaffold inhibits cells from migrating away from 
designated target location (i.e. physical barrier, chemical treatment, etc.) 
 Allow/facilitate formation of gap junctions, which are essential for the 
propagation of an electrical signal 
 Ability to be implanted into the ventricular septum 
 Interacts with the heart’s normal function – scaffold can withstand 
contractile forces of the heart 
 Support malfunctioning or damaged areas of the heart by allowing cells to 
pace the heart 
 Scaffold does not interfere with normal physiological functions 
 Scaffold should be permanent 
 Scaffold should be placed within close proximity of living myocytes 
 Scaffold does not impede electrical activity of the cells 
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Specifications 
 Cells cannot pass through the mesh (pore size will be less than 3 
micrometers) 
 Cells must contact myocytes to allow gap junction formation 
 Gap junctions should be able to form within 48 hours 
 
Constraints 
 Safety - scaffold should not degrade or break free 
 Scaffold should be biologically inert and biocompatible 
 Scar tissue formation should not impede gap junction formation 
 Size – should not drastically impede the normal mechanical function of 
the heart, necessary length to seed 700k cells 
 Scaffold should be implanted by means of minimally invasive surgery 
 Time – the project needs to be completed by April 30, 2009 
 Cost – the total cost of the project should not exceed $624 
 
After the functions of the device were identified, a functions means tree, shown in 
Figure 14, was constructed. The functions means tree allowed the team to visualize the 
scaffold’s functions and the possible approaches to attaining those functions.  
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Figure 14: Function Means Tree 
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Prioritization of Functions and Safety Measures 
 
Pairwise comparison charts were used during the engineering design process in order to 
identify which features of the design are most important (see Table 1). The two functions that the 
pairwise comparison charts analyzed were safety and first degree functions (degradability, 
biocompatibility, etc.) These two charts helped to prioritize what functions the group should be 
more concerned with when designing the cardiac scaffold. 
 
The first degree functions are defined as: 
 Degradability: the ability of the material to break down in a controlled manner and 
be absorbed by the body 
 Biocompatibility: the material causes little to no immune response (this includes 
minimizing the formation of scar tissue around the scaffold) 
 Immobilization: keeping the cells inside the scaffold rather than have them migrate 
around the heart or other areas of the body 
 Allow gap junction formation: gap junctions form in order to communicate with 
cardiomyocytes allowing it to pace the heart 
 Myocardium attachment: it will attach to the heart (either inside of the heart wall or 
just placed on the wall surface) 
 Mechanically stable: the material will not break down or deform due to the 
mechanical forces experienced when implanted in the heart. 
 
The safety functions are defined as: 
 Inflammatory: seriousness of inflammatory response to the implant in the heart 
 Thrombogenesis: risk of formation of blood clots 
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 Scar tissue: threat of scar tissue formation around the implanted material 
 Cell proliferation: stem cells dividing and growing inside of the scaffold 
 Migration: danger of stem cells migrating out of the scaffold 
 Toxicity: risks of having a toxic material in the heart 
 Implant complications: how important is it to keep in mind possible complications? 
Would a fail-safe mechanism be important to have? 
 Compliance mismatch: risks of mechanical mismatch between the implanted 
material and the heart (the material being either too soft or too hard) 
 Scaffold breaking free: dangers of scaffold breaking free, effects in the patient 
 Removability: importance of the scaffold’s ability to be removed after implantation 
in the event of any complication 
 Ease of implantation: importance of the material-user (doctor) interface in the 
moment of implanting the device 
 Integration: importance of the material being integrated by the body (cells 
interacting with the implant) 
 pH Balance: since implants can affect the pH balance of the surrounding area, 
evaluate the importance of controlling pH balance 
 
The two pairwise comparison charts were sent to and filled out by Professor Glenn 
Gaudette, Jacques Guyette, Joseph Dell'Orfano, MD, and Ira S. Cohen M.D., Ph.D. The chart is 
filled by writing either “0” (for not important) or “1” (for important) in the white boxes 
depending on the level of importance of the function being evaluated. The main function that is 
being rated is located horizontally while the vertical functions are the ones used for comparison.  
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For example, if degradability was more important than biocompatibility then the corresponding 
box would be filled in with a number “1”; but if immobilization was more important than 
degradability then a “0” would be written for that box.  
 
 
 
 
 
Table 2 shows the final percentages in order from highest to lowest with their 
corresponding function. To calculate the percentage of importance for each function, the 
Table 1: Pairwise Comparison Charts 
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averages were first taken for each row from each respondent. For example, if the four totals for 
degradability were 2, 3, 2, and 0, the average would be: 
2 + 3 + 2 + 0
4
=  1.75 
Biocompatibility should be the main priority and focus for first degree functions, followed by 
gap junction formation, myocardium attachment, mechanically stable, immobilization, and lastly, 
degradability. When designing the scaffold for safety, the concern with the scaffold breaking free 
is of greatest importance, followed by integration, toxicity, thrombogenesis, implant 
complications, scar tissue, migration, ease of implantation, inflammation, biomechanical 
mismatch, pH balance, cell proliferation, and removability.  
Table 2: Averages and Percentages  
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Chapter 4: Design Criteria  
Porosity 
 
In order to contain MSCs and allow the formation of gap junctions, the scaffold material 
must be porous. Pore size is critical; it must be large enough to allow for the passage of electrical 
signals yet not too large to permit leakage of stem cells (Rosen et al, 2004). Other factors beyond 
the diameter of the pore must be considered as well. When a biomaterial is subjected to 
compressive stress, the average size of the pores will decrease and thus the permeability of the 
material will lessen (O'Brien et al 2007). A study by O’Brien et al. concerning the porosity of a 
scaffold and its effects on stem cells showed that with increased pore size and permeability, 
greater levels of metabolic diffusion occur and consequently induce stem cell proliferation 
(O'Brien et al 2007).  
 
Too much porosity yields a negative effect that must be avoided in the design of a 
scaffold in the heart. Both of the studies verify the importance of selecting a critical pore size to 
achieve the desired functions, and based on their experimental results and the known properties 
of MSCs, an optimal pore size will likely be between 0.5-10μm.  
 
Strength 
The scaffold must be strong enough to withstand the contractile/relaxation motion of the 
heart, yet flexible and adaptable to allow mesenchymal stem cells to proliferate. The strength of 
heart contraction and relaxation is measured through blood pressure. The systolic measurement 
is the force at which the heart contracts to pump blood into the arteries and to the rest of the 
body. A healthy heart should not pump blood at a greater pressure than 120mmHg. The diastolic 
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pressure is the force at which the arteries relax. A healthy heart should yield a diastolic pressure 
of approximately 80mmHg (American Heart Association, 2008). A scaffold material subjected to 
the systolic and diastolic pressure must withstand forces higher than 120/80mmHg respectively, 
to ensure that it will not break under repeated contractile and relaxation forces. 
The scaffold material must also be flexible to allow mesenchymal stem cell proliferation 
and ease implantation. The stem cells must be able to proliferate within the scaffold to ensure 
that as old cells die, new ones are generated to facilitate the communication with cardiac 
myocytes. Over-proliferation is not a concern in the design of the scaffold as MSCs are 
attachment dependent: they will adhere to the inner wall of the scaffold and will not be 
concentrated in the center. As a result, this cell distribution will not impose any mechanical 
stress on the scaffold that could potentially cause it to burst. Figure 15 shows a distribution of 
MSCs as they would appear adhered to a surface. 
 
Figure 15: Human MSCs attached to a material surface (Plopper, 2008) 
 
Lastly, the material must be simple to implant into the ventricular septum through the use 
of a catheter. This minimally invasive approach will require a flexible and injectable material to 
effectively be inserted.  
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Preliminary Designs 
The design team drafted various conceptual designs which are located in Appendix B. 
Based on those early ideas the team prepared two preliminary designs. One is a fibrous cross-
linked scaffold and the second a hollow scaffold with pores. Both will be in the shape of a 
football, with the inside being hollow to allow cells to be held inside. Both designs look to 
maximize the surface area with which the modified hMSCs could form gap junctions with 
cardiac myocytes. The main difference between the designs depends on the manufacturing 
technique: the cross-linked scaffold will need to be electrospun while the alternative design will 
utilize solvent casting or particulate leaching.  
Cross-linked Scaffold 
One conceptual design is a cross-linked scaffold. For this design, the fibers of the 
biomaterial will be interwoven via electrospinning (see Figure 16; note: the diagram is not scaled 
to size). For this design the material would first be electrospun into the football shape; this shape 
allows for a maximized surface area for the cells to attach to in order to form gap junctions. The 
cells would then be injected through the ends of the scaffold. A concern with this design, 
however, is closing off the ends once the cells have been injected. If the ends were to be left 
open, an infection could occur. This would result in the patient needing to go through an 
additional surgery to remove the infection from the heart before further complications resulted.  
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   a) Side view            b) Front View   
 
Scaffold with Pores 
The second conceptual design is a scaffold that contains a hollow interior with scattered 
pores located on all sides of the exterior (see Figure 17; note: the diagram is not scaled to size). 
The hMSCs will be placed on the inside of this scaffold, allowing for gap junction formation 
through the pores. One advantage this design has over the electrospun design is that the pore size 
can be more controlled and concise since it will be produced using solvent casting or particulate 
leaching. A major disadvantage of this design, similar to that of the electrospun scaffold, is the 
empty space where the cells will be located, allowing for the potential for bacteria to grow and 
produce an infection. Another disadvantage of this design is that there will be fewer pores than 
the electrospun scaffold for the cells to form gap junctions with. 
 
a) Schematic Drawing 
 
 
b) Front View 
  
Figure 16:  Cross-linked Scaffold 
Figure 17: Scaffold with Pores 
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Material Analysis  
In order to appropriately choose a material capable of withstanding the mechanical 
stresses of the heart, preventing human mesenchymal stem cell migration and other 
complications, common materials being employed in cardiovascular applications were evaluated. 
The three most common materials utilized for the production of synthetic vascular grafts are 
Polyethylene Terephthalate (PET) also known in the medical industry as Dacron, 
Polytetrafluoroethylene (PTFE), and Polyurethane (InspiredMD Corporation, 2005). In addition, 
Nitinol is a main component of the vascular stent business due to its particular properties. Table 
3 summarizes the team’s findings regarding material properties. A sumary of the materials’ 
characterisitcs under each condition evaluated can be found in Table 4. 
Table 3: Summary of Candidate Material Properties 
 Nitinol Dacron (PET) ePTFE Polyurethane 
(ChronoFlex® C) 
Biocompatible Yes Yes Yes Yes 
Citotoxic no no no no 
Elastic Modulus 1160-1200 *10^4 psi 40-60*10^4 psi 5.8-8.01* 10^4 psi 0.775-1.9*10^4 psi 
UTS 28.3-100 ksi 7.01-10.5 ksi 2.9-4.35 ksi 5.5-7.5 ksi 
Yield Strength 
(Elastic limit) 
129-276 ksi 8.19-9.04 ksi 2.18-3.63 ksi --- 
Multiaxial fatigue --- 2.8-4.2 ksi  
(at 10^7 cycles) 
0.834-1.02 ksi  
(at 10^7 cycles) 
--- 
Shear Modulus 4.35-4.69*10^6 psi 0.144-0.216*10^6 psi 0.02-.0276*10^6 psi --- 
 
After evaluating the possible biomaterials that were suitable for cardiovascular 
applications, the team decided to use polyurethane as the material for the cardiac scaffold. This 
decision was based on the material’s mechanical properties, biocompatibility, corrosion and wear 
resistance, cost, availability, and manufacturability to the team’s specifications. 
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Table 4: Qualitative Material Description 
Material 
Mechanical 
Properties 
Bio/Hemo- 
compatibility 
Corrosion & 
wear 
resistance 
Availability 
Ease of 
manufacturing 
 
Dacron 
 
may kink 
Susceptible to 
fibrotic 
encapsulation 
and infection 
Can degrade × easy 
 
Nitinol 
 
Shape memory, 
strong 
excellent 
Oxide layer 
protects 
surface from 
corrosion and 
degradation 
 
fair 
 
ePTFE 
 
Change 
drastically over 
time 
Can ward off 
infections 
Can degrade 
 
fair 
 
Polyurethane 
 
Durable, 
resistant to 
fatigue, elastic 
and compliant 
to surrounding 
cardiac tissue 
Not cytotoxic to 
cells, no 
thrombus 
formation 
observed, 
resistant to 
bacteria 
Does not 
degrade over 
time (durable) 
 
easy 
 
Table 5 shows the results stated above just as positive (+) and negative (-) signs to 
represent the material’s performance under each category. The last column displays the total of 
positive signs for each material. The total numbers were used to evaluate the most appropriate 
material for the design of the scaffold. As seen in the chart results, polyurethane has the highest 
number of positive aspects; therefore, polyurethane is the best-suited material for the cardiac 
scaffold design.  
Table 5: Material Summary 
Material 
Mechanical 
Properties 
Bio/Hemo- 
compatibility 
Corrosion & 
wear resistance 
Availability 
Ease of 
manufacturing 
Total 
+ 
Dacron - - - - + 1 
Nitinol + + + + -  4 
ePTFE - + - + - 2 
Polyurethane + + + + + 5 
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The polyurethane brand obtained for the purpose of our project was Chronoflex® C 
developed by AdvanSource Biomaterials. Chronoflex® C is an aromatic thermoplastic 
polyurethane especially designed for biodurability by preventing surface degradation caused by 
stresses from the surrounding environment (ChronoFlex, 2008). If needed, this material could be 
compounded for radiopacity (ChronoFlex, 2008), allowing the team to track the scaffold after 
implantation through imaging technologies. The implementation of Chronoflex® C in 
biomedical devices is not regulated under a specific FDA regulation (ChronoFlex, 2008) which 
would require a specific FDA approval for the team’s application before human trials could 
commence. The full material analysis and AdvanSource’s specification sheets on Chronoflex® C 
can be seen in Appendix C.  
Material Processing  
Once the Chronoflex® C polyurethane was acquired from AdvanSource Biomaterials, the 
group worked with Matt Phaneuf and Saif Pathan of Biosurfaces, Inc. (Ashland, MA). Matt and 
Saif were able to successfully electrospin the polyurethane pellets into thin microporous sheets. 
In order to provide the group with a sheet that was as close to the desired specifications as 
possible, there were several settings that had to be considered. One such setting was the distance 
from the needle to the collecting plate (a distance of 15cm was chosen for application). If this 
distance was increased, the result would have been thinner fibers and thinner pores. While 
electrospinning the material, a 10% weight to volume ratio of polyurethane was used. A 20kV 
voltage was applied to the polyurethane which was sprayed out at a rate of 3mL/hr. Polyurethane 
membranes were electrospun at three different time intervals: 30 minutes, 60 minutes, and 90 
minutes (n=1 for each time). The average sheet thickness for a 60 minute electrospun sample was 
approximately 50μm.  
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Chapter 5: Design Verification 
Culturing Mesenchymal Stem Cells 
The following material is taken from the advice of Jacques Guyette, a PhD grad student 
in the Biomedical Engineering Department at Worcester Polytechnic Institute. Caring for the 
human mesenchymal stem cells requires diligent attention to detail. The first care item is 
preparation of media to sustain the cells. The media was prepared in the sterile hood and contains 
500mL of DMEM as the base. To this 50mL of fetal bovine serum (FBS) and 5mL of PenStrep 
was added to create a 10% FBS and 1% PenStrep solution. The media, which needs to be 
replaced every 2-3 days, was placed in three 50mL conical tube aliquots and ten 15mL conical 
tube aliquots. The rest was left in the original DMEM container. The cells were grown in a T75 
size flask which only required 8mL of media.  
Human mesenchymal stem cells are attachment dependent. In order to remove them from 
their T75 flask and separate them into two flasks (or utilize for experiments) it was necessary to 
break down the extracellular matrix which holds the cells to the surface of the container. This 
was done by first removing the media in the flask and adding 7mL of trypsin to the cells; trypsin 
is a protease which breaks down protein (Guyette, 2008). After 10 minutes the flask was checked 
under the inverted microscope, and if, when agitated, cells were seen to shift and float, the 
solution was ready to be spun. It is important not to leave the trypsin activated with the cells for 
longer than 15 minutes. This is because the trypsin will begin to break down the cells 
themselves. The cells + trypsin were added to a 15mL conical tube with 4mL of fresh media. The 
fetal bovine serum in the media deactivates the trypsin. Putting this 11mL cell, deactivated 
trypsin, and media into a centrifuge with a counter weight, it was spun at a low velocity for 5 
minutes. Upon taking the conical tube out of the centrifuge, the dilatant media is on top and the 
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cell pellet at the bottom. The dilatant was removed and 1mL of fresh media was added to the cell 
pellet. After the cells were re-suspended in the new media, the number of cells had to be counted. 
This was done by taking 10μL of the cell suspension and adding it to a small tube of 40μL trypan 
blue and 50μL of Phosphate-buffered saline (PBS). After mixing this mixture well, 10μL of the 
solution was carefully added to each side of a hemocytometer. The cells were counted in the 
hemocytometer using the inverted microscope. 
Experimental Design 
After the design criteria were identified and the materials had been selected, testing was 
necessary to ensure that the device would meet all requirements. The testing of medical devices 
must follow strict protocols established by the Food and Drug Administration (FDA), which 
classifies all medical devices into one of three classes. Class I devices are those that pose 
minimal harm, either to the patient or the user. Consequently, they require the least amount of 
regulatory control. Examples of Class I devices include bandages and latex gloves (Device 
Classes, 2002). Class II devices are those that pose potential harm, and thus require general and 
special controls. Special controls may indicate specific labeling requirements or specific 
performance criteria. Examples of Class II devices include powered wheel chairs and infusion 
pumps (Device Classes, 2002). Lastly, Class III devices are those that pose the most danger and 
thus require the strictest regulation. Premarket approval is required for most Class III devices 
before testing can commence. In order to gain premarket approval, an application must be filed 
and a review committee will then determine whether or not the device is safe and effective. Class 
III devices include any life-sustaining implant such as pacemakers and endosseus devices 
(Device Classes, 2002). 
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A cardiac scaffold implanted in the heart would be classified as a Class III medical 
device as it poses great potential harm. The implantation procedure itself is dangerous, and if the 
device malfunctions, the consequences of its failure could be fatal. Thus, in order to be approved 
by the FDA, the effectiveness of the device must be shown. Additionally, the device should be 
designed to be as safe as possible to diminish potential harm. 
As with all Class III devices, the criteria the device must meet will be strict. 
Organizations such as the American Society for Testing Materials (ASTM) write standard tests 
that can be done to validate the properties of specific materials. The International Standards 
Institute (ISO) is another organization that writes standards that researchers, scientists, 
manufacturers and more must comply with in order to effectively bring a product to market 
(Ratner, 2004). This section identifies some of the tests and standards that a cardiac scaffold 
device must meet in order to obtain approval. 
Preparing for Cell Assays  
Prior to using the electrospun samples to carry out the Migration Assay, Cell Viability 
Assay, and the Connexin Assay, the group needed to sterilize the polyurethane sheets. This was 
done by first soaking them in 70% ethanol for approximately two hours. Afterwards, they were 
soaked in distilled water for two hours and allowed to dry in a sterile air hood overnight. 
Furthermore, the group needed to have special wells manufactured in order to perform 
these assays. The group used a core design created by Professor George Pins (Worcester 
Polytechnic Institute, MA) where a sheet of material is clamped between two caps. The group 
altered the design slightly to increase the ease with which the wells could be manufactured, and 
then had Giacomo Ferraro (Worcester Polytechnic Institute, MA) machine the wells out of a 
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Lexan plastic. These wells, as seen in Figure 18 and termed “Gaudette-Pins wells”, are 
autoclavable and allowed for the group to carry out all the necessary assays. 
 
 
Figure 18: Custom built wells which house the polyurethane scaffold and allow for the seeding of cells on both 
the upper and lower side 
Pore Size Migration Assay 
Migration of non-terminally differentiated stem cells from target sites is a current concern 
around stem cell based therapies. In this context, the migration of modified hMSCs migrating 
away from the heart and differentiating could cause unpredictable effects on the body. A direct 
effect could be multiple concentrations of modified hMSCs settling at different sections of the 
heart. This could mean multiple action potentials initiating simultaneously at different locations 
of the heart resulting in fibrillation. For these reasons limiting and ideally preventing migration 
all together is a key function of the design. 
 
Figure 19: Preliminary Design of Stem Cell Scaffold 
 
 
To limit migration, the team proposed to create a porous mesh (See Figure 19). An 
integral aspect of this design is the pore size of the mesh. Ritter et. al, investigated the migratory 
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effects of Basic Fibroblast Growth Factor (FGF-2) on human mesenchymal stem cells (2008). In 
a Transwell migration assay (Boyden assay), they found hMSCs migrated through 8μm pores 
when FGF was used as a chemoattractant in excess of 20ng/mL. Although Ritter et. al, found 
that breast cancer derived FGF-2 and Vascular Endothelial Growth Factor (VEGF) both induced 
attractive migration of human mesenchymal stem cells, in vitro concentrations were similar and 
FGF-2 costs less to obtain (Invitrogen, Carlsbad, CA). In addition to 8μm pores, the team 
utilized 3μm and 0.4μm pore Transwells (NUNC, Rochester, NY) to determine the pore size at 
which hMSCs cannot migrate. See Figure 20 for test representation. A concentration of 30ng/mL 
placed in the lower compartment with 400μL of DMEM media simulated double the 
physiological concentration of FGF-2. 100,000 hMSCs were seeded on the upper part of the 
microporous membrane and incubated for 3 days at 37
o
C and 5% CO2. Migration of cells was 
quantified using Hoechst and Phalloidin staining for cell nuclei and cytoplasm, respectively.  
 
 
Figure 20: Pore Size Test (Corning Transwell® Permeable Supports) 
 
Quantifying hMSC Migration 
In order to quantify the results from the pore size migration assay, Hoechst and Phalloidin 
stains were used on both the wells and the well inserts to fluorescently label cells. The Hoechst 
stain was used to label the nucleus of the hMSC, while the Phalloidin stain identified the cellular 
cytoplasm. The following protocol was used to stain for stem cell migration: 
1. Remove the well insert from the well and place into another sterile well. Rinse both in 
PBS solution for 5 minutes. 
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2. Remove the PBS solution and re-rinse both the well and the insert in PBS for another 5 
minutes. 
3. Remove the PBS solution. Place 4% paraformaldehyde at the bottom of the well and 
insert for a total of 10 minutes to fix the cells. 
4. Remove the paraformaldehyde and rinse with PBS solution for 5 minutes. 
5. Remove the PBS solution and re-rinse both the well and the insert in PBS for another 5 
minutes. 
6. Remove the PBS solution. Place .25% Triton-X (in PBS) onto the well and insert for a 
total of 10 minutes. 
7. Remove the Triton-X and rinse with PBS solution for 5 minutes. 
8. Remove the PBS solution and rinse with 1% Bovine Serum Albumin (BSA) in PBS for 
10 minutes. 
9. Remove the PBS/BSA and place Alexa Fluor 488 Phalloidin stain (5L Phalloidin per 
200L PBS) on the samples for 30 minutes. 
10. Remove the stain and rinse with PBS/BSA for 10 minutes. 
11. Remove the PBS/BSA and re-rinse with more PBS/BSA for 10 minutes.  
12. Remove the PBS/BSA and re-rinse with more PBS/BSA for another 10 minutes.  
13. Remove the PBS/BSA and place Hoechst 3342 Trihydrochloride Trihydrate stain 
(10L/1mL Distilled Water) on the samples for 5 minutes. 
14. Remove the stain and rinse with PBS/BSA for 5 minutes. 
15. Remove the PBS/BSA and place pure PBS onto the samples. 
16. Examine the samples under a fluorescent microscope. 
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Scaffold Gap Junction Formation Assay  
Another important aspect of the team’s design is whether the hMSCs form gap junctions 
through the porous polyurethane. In order to test this, the team proposed to do another Transwell 
assay. The difference being that whereas the pore size was evaluated utilizing migration across 
industrial standard polycarbonate transwells, this assay looked at gap junction formation across a 
polyurethane microporous membrane. After the results of the pore size assay are complete, the 
team will know the range of pore sizes with which to construct the polyurethane scaffold. Instead 
of seeding a single cell layer on the upper portion of the porous membrane, it was necessary to 
have one layer of cells on each side of the microporous polyurethane membrane. See Figure 21 
for assay representation. The cells needed to be geared towards gap junction formation. It would 
be ideal to place myocytes obtained from mice or dogs across from the hMSCs; however 
obtaining cardiac myocytes is difficult and mantaining in culture is also very challenging. 
Another option would be to obtain special connexin 43 expressing cells, but again these cells are 
delicate and expensive. The cost effective solution was to seed hMSCs on both layers. Using 
connexin 43 staining and confocal microscopy it was possible to determine gap junction 
formation across the pores. After seeding and the appropriate tracking (quantum dot) the system 
was incubated for 48 hours and stained for connexin 43. See Figure 21 for design specification of 
custom built dual well for gap junction assay.  
 
Figure 20: Two layers of hMSCs across a microporous polyurethane membrane 
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Figure 21: Gaudette-Pins Dual Transwell Design 
Gap Junction and Live/Dead Immunohistochemistry  
In order to determine whether gap junctions form between the polyurethane membrane, 
connexin 43 (the primary protein in gap junctions) staining was conducted. The following was 
the procedure for connexin 43 staining; Figures 22 and 23 are representative images of tissue 
controls and cell samples.  
1. Fix cells in cold acetone for 10 minutes at -200C 
2. Rinse twice with PBS 5 minutes each wash 
3. Rinse with Triton X for 10 minutes 
4. Block with 1.5% Normal Rabbit Serum (NRS) at room temperature for 1 hour 
5. Add primary anti-body (mouse anti-connexin) at 1:250 concentration in 1.5% NRS and 
incubate overnight at -20
0
C 
6. Rinse 3 times with PBS for 5 minutes each 
7. Add secondary anti-body (Alexa Flour 488 rabbit anti-mouse at 1:400 concentration in 
1.5% NRS for one hour (Light Sensitive – Keep covered after this step) 
8. Rinse with PBS 5 minutes 
9. DAPI counterstain  
10. Observe results  
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Figure 22: Positive (left) and Negative (right) Tissue Control Slides 40x 
 
 
Figure 23: Positive Cell Samples at 40x (left) and 20x (right) 
 
It was also necessary to determine cell viability on the polyurethane scaffold. To this end, 
the team performed Live/Dead staining. Proper concentrations for the solutions were previously 
determined by Jacques Guyette. For live hMSCs the fluorescent dye calcein was used at a 
concentration of 1µMolar. For dead hMSCs, Ethidium Bromide was used at a concentration of 8 
µMolar. Figure 24 shows representative images of Live/Dead staining results. The following 
protocol for Live/Dead is very straightforward.  
1. Create a combined solution of the two dyes in sterile PBS at the appropriate 
concentrations. 
2. Add the solution to the cells 
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3. Cover 
4. Incubate for 20 minutes at 370C 
5. Add fresh Live/Dead solution or PBS to wash cells. 
6. Observe cells. 
 
Figure 24: Sample Staining of Dead (left) and Live (right) cells 
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Chapter 6: Experimental Results and Discussion 
Pore Size Migration Assay – Trial 1 
 
For the first trial of the pore size migration assay, three separate items were stained: the 
bottom of the wells after 3 days of incubation, the bottom of the wells after 11 days of 
incubation, and the well inserts themselves after 11 days of incubation. Staining of the wells used 
for the 8m pore inserts showed that only 3-4 hMSCs passed through after 3 days of incubation; 
however, after 11 days, a significantly larger amount of cells had passed through. In some of the 
wells, over 20 hMSCs had migrated through. With the 3m inserts, only 1-2 cells were seen in 
the wells for both 3 and 11 days worth of incubation. Staining of the wells used in conjunction 
with the 0.4m inserts showed no signs of cell migration. Figure 25 below shows some of the 
images that were obtained from the first trial. 
 
  
Figure 25: Bottom of 8 µm insert (left) and bottom of well (right) 
 
This trial helped to provide some supporting evidence as to the proper pore size for the 
scaffold. Based on the results, it appears that the proper pore size will be between 0.4m and 
3m. While a minimal amount of cells passed through the 3m pores, no cells seemed to pass 
through the 0.4m pores, which suggests that the pore size will probably be around 1m to 2m. 
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While this data was informative, there were a couple of limitations with this trial. The 
first was that no controls were used. For the next trial, positive controls (wells with hMSCs 
seeded at the bottom) and negative controls (wells and inserts with just media) will be used so 
that the team can more subjectively determine cell migration.  
Another limitation of this trial was that the bottom of the wells was used to quantify stem 
cell migration. Although this provided some information, hMSCs are attachment dependent; it is 
unlikely that a large amount of cells would detach and sink to the bottom of the well. The cells 
would be more likely to migrate through the pores to the other side of the well. Although these 
cells did not float away, they were still able to migrate through the pore size (meaning that a 
smaller sized pore would be needed for the scaffold).  
In order to obtain more valid results, the second trial will also look at the bottom side of 
the well insert. The top part of the well insert will be scraped to remove any cells that did not 
migrate through, and then the remaining cells will be stained to identify migration. This 
methodology was effectively used by researchers who performed a similar transwell migration 
assay (Forte et al, 2006). 
Once a proper pore size range has been confirmed, a similar assay will be conducted 
using a polyurethane scaffold instead of the polycarbonate well inserts. Scaffolds with various 
pore sizes will be used to ultimately determine what the necessary pore size must be. 
 
Pore Size Migration Assay – Trial 2 
 
The second trial of this assay had a similar setup to the previous run, but with only 0.4 
micron and 3 micron porous wells. Again, a FGF based chemoattractant was used to help induce 
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migration of the hMSCs (approximately 55ng/mL) and roughly 50,000 cells were allowed to 
incubate within the wells for 3 days before the staining procedures were carried out. 
The limitations associated with the initial trial of the Migration Assay were also 
addressed in this run. In order to have some experimental control, both a positive and negative 
control were used in order to more accurately identify the migration of a stem cell through a 
pore. For the positive control, hMSCs were seeded on the reverse side of the well; for the 
negative control, only media was put into the well. 
The other major drawback with the initial trial was addressed in how the wells were 
analyzed. The initial run looked at cells which had completely passed through the well and 
seeded to the bottom of the plate. However, it is more likely for the stem cells to migrate from 
the upper side of the well to the lower portion through the porous membrane. In order to identify 
this style of migration, the wells were examined prior to and after scraping the upper portion of 
well membrane.  
After completing the staining, the 0.4 micron wells were analyzed with an inverted 
fluorescent microscope. When examining the wells prior to scraping them, it was apparent that 
there were still cells on the membrane, either on the upper or lower surface. After scraping the 
upper surface with a q-tip, the wells were re-examined, which showed evidence of no cell 
migration to the opposite side of the well. Figure 26 contains representative images of the 0.4 
micron wells, both before and after scraping. 
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Figure 26: .4 micron wells prior to scraping (left) and post scraping (right) 
 
 
Similar to the 0.4 micron wells, an initial look with the scope revealed a mass of cells on 
the 3 micron wells. However, after scraping the wells with a q-tip, there was still a significant 
amount of cells. This confirms the belief that the 3 micron pores are too large, which allow for 
the cells to migrate through to the other side. Figure 27 below shows the representative images. 
 
 
Figure 27: 3 micron wells prior to scraping (left) and post scraping (right) 
 
. 
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Cell Viability Assay 
 
The results from the cell viability assay showed a mixed bag of live and dead fluorescent 
signal. For the most part there was live signal as shown in Figure 28. The controls had a much 
brighter signal for both live and dead. Live signal is represented by green while dead cells show 
up as red. The polyurethane isn’t completely transparent so it could have played a role in the 
reduced signal. In addition, the formation of gap junctions among the cells demonstrated cell 
viability on the polyurethane. The next section goes into detail about gap junction formation.  
 
Figure 28: Live/Dead Results 
 
Gap Junction Assay Results 
 
Cells were seeded on both sides of the polyurethane scaffold suspended in the Gaudette-
Pins dual well and allowed to incubate for 48 hours. Staining with controls was conducted as 
outlined in the methodology. Confocal microscopy was used to determine gap junction formation 
through the polyurethane. Confocal microscopes allowed for visualization in the x-, y-, and z- 
planes, Figure 30 shows a 3-D projection of the cell seeded polyurethane. The nuclei (blue 
circles) on the far sides represent cells on opposite sides of the polyurethane. As seen in Figure 
29 there is nuclei signal and gap junction (green) signal between the polyurethane scaffolds. The 
results demonstrate that formation of gap junctions through the scaffold is possible.  
59 
 
  
Figure 29: 3D Gap Junction Formation through Polyurethane 
 
Migration through Polyurethane  
 
As stated, one of the potential limitations with the electrospun polyurethane is the lack of 
a precisely controlled pore size. In order to ensure that the gap junctions seen in the previous 
assay were formed through a barrier that limited migration, another migration assay was 
conducted. All test parameters remained the same, except this time the specially manufactured 
wells were used. Quantifying migration for this round of experiments was less complicated 
because the polyurethane sheets were not transparent. Therefore, no scraping was necessary; 
when being examined with the fluorescent scope, the group could just flip over the custom made 
well to examine the other side.  
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Overall, results from the test showed that no cells were able to pass through the 30, 60, or 
90 minute electrospun microporous sheets. This means that the settings with which Biosurfaces, 
Inc. electrospun the polyurethane would prevent migration of the cells and allow for the 
formation of gap junctions. Figure 30 shows the difference between the side of 60 minute sheet 
on which cells were seeded, and the opposite side (where the hMSCs could not migrate to). 
 
 
Figure 30: Human Mesenchymal Stem Cells on one side of the polyurethane sheet after 3 days of incubation (left); 
Reverse side of the same polyurethane sheet, where no cells were able to migrate to (right) 
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Mechanical Calculations 
Deflection of a hMSC 
 
Based on the pore-size testing results, the pore size of the electrospun polyurethane 
should be between 0.4-3.0μm.  However, this is a wide range and doesn’t provide a specific 
enough result; therefore, to obtain a better pore-size approximation, the deflection of an hMSC 
was calculated mathematically at different pore-sizes. 
The main importance of these calculations was that it allowed the design team to 
determine what the fiber diameter should be of the electrospun polyurethane.  In order for gap 
junctions to occur, both the pore size and fiber diameter had to be balanced so that cells on 
opposite ends of the fiber deflect and touch each other.  If these two parameters are not 
appropriately balanced, either the cells will not come into contact with each other or the cells 
will migrate through to the opposing end of the fiber.  
To begin the calculations, it was assumed that the cell was in the shape of a beam.  From 
literature, it was determined that a cell has a length of 10.0μm and a thickness of 2.0μm (Tastan, 
et. al., 2009).  It was also assumed that there was a uniform load distribution on the cell caused 
by the beating heart (see Figure 31). 
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Figure 31: Free Body Diagram of a hMSC 
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As part of the derivation for deflection, the maximum deflection would occur at 𝑥 =
𝐿
2
; 
based on this, the maximum deflection equation is: 
𝐸𝑞. 1              ∆𝑚𝑎𝑥  =
5𝑤𝐿4
384𝐸𝐼
 , 
where E is the Young’s Modulus of a hMSC, I is the moment of inertia of the hMSC, L is the 
length between fibers (the pore-size), and w is the force per unit length (see Appendix D for full 
derivation).  The constants obtained from literature were Young’s Modulus and the pressure 
exerted by the intramyocardial wall.  In a study conducted by Tan, et. al. (2008), it was 
determined that at human body temperature (37°C), the Young’s Modulus of an hMSC is 
126±81Pa.  For the intramyocardial pressure constant, Heineman et. al. (1985) determined that 
there was a range of 5±2mmHg.  The mean value (5mmHg) was then used to determine the force 
per unit length exerted onto the cell at various pore sizes. 
To calculate the moment of inertia, it was assumed that the shape of the cell was 
elliptical.  For a quarter of an ellipse, the moment of inertia equation is: 
𝐸𝑞. 2                    𝐼 =
𝜋𝑎𝑏3
16
 , 
where a and b are defined in Figure 32. 
. 
 
 
 
 
 
Figure 32: Moment of Inertia of a hMSC 
 
a 
b 
1.0 μm 
5.0 μm 
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This equation was modified in order to calculate the moment of inertia of a full ellipse.  
To do this, the quarter ellipse equation was multiplied by four, which resulted in the following 
equation: 
𝐸𝑞. 3                     𝐼 =
𝜋𝑎𝑏3
4
  . 
After the variables a and b were plugged into the former equation, the resulting moment 
of inertia of a hMSC is 3.93μm4.   
The last variable included in the maximum deflection equation, L, varied from 0.4 to 
3.0μm.  For the calculation, increments of 0.5 were used from 1.0 to 3.0μm; no increments were 
used between 0.4 and 1.0μm. 
The calculations for the maximum deflection were completed using MatLab.  An 
example of the syntax used in MatLab is shown in Figure 33.  For all MatLab coding, see 
Appendix E. 
 
Figure 33:  MatLab Syntax 
 
Upon completing all the calculations, the team decided the most desirable pore-size 
would be between 2.0 and 2.5μm (see Table 6; for all results, see Appendix F) because it would 
result in a more manageable fiber thickness.  The average deflection length between 2.0 and 
2.5μm is 15-30μm.  Therefore, the fiber diameter would need to be double the deflection length 
in order to account for cells deflecting on opposite sides of the fiber and forming gap junctions.  
As a result, the fiber diameter should be approximately 30-60μm.  
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Figure 34 represents the correlation between the length between fibers and the Young’s 
Modulus.  As the pore size increases, the deflection also increases; as Young’s Modulus 
increases, the deflection decreases.   
 
 
 
Figure 34:  Deflection vs. Pore Size and Young's Modulus 
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Pore size (micrometers)
Deflection at 5mmHg
E=45 Pa
E=126 Pa
E=207 Pa
Length between Fibers = 2.0 μm 
Pressure (Pa) E (Pa) d (μm) 
133.3 
45 6.16 
126 2.2 
207 1.34 
266.6 
45 12.34 
126 4.41 
207 2.68 
666.6 
45 30.86 
126 11.02 
207 6.71 
799.9 
45 37.03 
126 13.23 
207 8.05 
Length between Fibers = 2.5 μm 
Pressure (Pa) E (Pa) d (μm) 
133.3 
45 12.03 
126 4.3 
207 2.61 
266.6 
45 24.11 
126 8.61 
207 5.24 
666.6 
45 60.28 
126 21.53 
207 13.1 
799.9 
45 72.33 
126 25.83 
207 15.72 
a)   Calculation results for L=2.0μm b)   Calculation results for L=2.5μm 
Table 6: Calculation Results 
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Cell Quantity Threshold  
 
The design team contacted Dr. Ira Cohen of SUNY Stony Brook University via e-mail to 
inquire about the number of modified hMSCs required to replace the function of the sinoatrial 
node. He responded that his team estimates 350,000 cells fully restore function, but with only 
50% transfection efficiency they inject 700,000. In order to have a safety factor of two, the team 
decided to seed 700,000 onto the scaffold. Therefore, the area of the collected cells and the 
surface area of the scaffold both needed to be calculated to determine appropriate dimensions for 
the scaffold. 
To calculate the area of a cell, the diameter of a cell used was 10μm, as used in the 
deflection calculations. The following formula was used to determine the surface area needed for 
700,000 cells: 
𝐸𝑞. 4           𝐴𝑐𝑒𝑙𝑙 =  𝜋𝑟
2 ∗ 700,000 . 
The calculated surface area was 55.0 mm
2
 for 700,000 cells. 
Economic, Environmental, and Ethical Impacts 
 
 While this project solely focused on the concept of limiting migration of stem cells, if the 
overall technology and research of a biological pacemaker reaches the point where it can be used 
effectively to pace the heart, it would allow for patients to undergo one surgery to fix any 
arrhythmia problems.  This reduces the overall impact on the health care and economic system, 
since the cost of repeated surgeries to replace pacemakers would be decreased. 
Overall, the cost of producing a biological pacemaker is less than that of the artificial 
pacemaker; therefore, the benefits of this product can reach people who may not normally have 
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been able to afford it.  This would positively impact people not only in this country, but around 
the world as well. 
As for environmental concerns, there are no major environmental impacts that result from 
this product.  The overall cost of production and the cost of material is minimal when producing 
this product.  Also, the biological pacemaker works with the body, so once the scaffold is 
produced and implanted; it does not need to be replaced.  That way, there are no pacemakers or 
batteries to discard. 
 Lastly, the ethical considerations revolving around human mesenchymal stem cells are 
minimal since they are taken from each individual pacemaker.  If the system revolved around 
embryonic stem cells, the ethical debates would be more significant. 
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Chapter 7: Final Design  
 
Based on initial migration assays, the mechanical calculations, considerations for 
minimally invasive delivery through a catheter, and development of the team’s preliminary 
designs; the team proposes the final design seen in Figure 35. The design consists of a two part 
cylindrical scaffold. The cylindrical shape was chosen because it resembled the shape of stents, 
which are widely used in the cardiac industry. The blue section is a solid cylinder composed of 
ChronoFlex® C. The purpose of this solid cylinder is to provide mechanical support to the 
scaffold. The red section represents a porous electrospun ChronoFlex® C film on which the 
modified hMSCs are seeded. This membrane is thin enough to allow for cellular communication 
across the scaffold and the pores are sized to prevent cells from migrating through to the other 
side. The team worked with Biosurfaces, Inc., who made the electrospun ChronoFlex® C 
membrane for this project. After cellular adhesion, the porous film is wrapped around the solid 
polyurethane cylinder. To finalize the scaffold, sealing bands and caps in conjunction with 
BioGlue® are added to prevent hMSC migration out of the scaffold from the sides of the 
cylinder. Another function of the sealing bands and caps is to protect the porous membrane from 
the shear stresses the scaffold might experience during delivery. 
 
Figure 35: Final Design Representation 
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Following the recommendation of Professor Glenn Gaudette and using current cardiac 
catheter sizes as a guide to develop the scaffold, the team chose an outer diameter of 1.0mm for 
the solid polyurethane component of the design. The minimum length of the scaffold was then 
calculated taking into consideration the amount of surface area needed to seed 700, 000 cells 
(amount of cells seeded to induce pacemaker function in the heart) onto the surface of the porous 
membrane. Because the electrospun polyurethane is in the shape of a cylinder; the following 
surface area equation was used:  
𝐸𝑞. 5                𝑆𝐴𝑐𝑦𝑙𝑖𝑛𝑑𝑒𝑟 = 2𝜋𝑟
2 + 2𝜋𝑟𝑙 , 
where r is the radius of the solid polyurethane scaffold, SA is the surface area of the 700,000 
cells and l is the minimum length of polyurethane needed. After the variables were plugged into 
this equation, it was determined that the length needed was 17.0 mm. 
The deflection calculations determined that the desired electrospun membrane thickness 
was between 30 and 60μm, and from both the deflection calculations and the pore size migration 
assay it was determined that the appropriate pore size was between 2.0 and 2.5μm. 
 
Fibrin Glue 
In order to seal the scaffold, the team plans to use sealing bands and caps in conjunction 
with BioGlue®. BioGlue is a surgical adhesive developed by CryoLife that has been specially 
designed for the use in cardiovascular surgery. It is composed of purified bovine serum albumin 
(BSA) and gluteraldehyde that are packaged in two separate chambers of a syringe as shown in 
Figure 36 (CryoLife, 2008). 
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Figure 36: BioGlue® syringe (CryoLife, 2008) 
 
When the BioGlue is delivered, the two components mix and create a chemical reaction 
that causes the two materials to cross-link. The molecules of gluteraldehyde bond with the BSA 
molecules and when the mix becomes in contact with the proteins at the repair site, it creates a 
flexible mechanical seal that does not depend on the body’s clotting mechanism (CryoLife, 
2008). 
 The advantage of using this adhesive is that it starts to polymerize within 20 to 30 
seconds after mixing, and at two minutes, it is strong enough to bond things together. This 
adhesive is useful for bonding biological tissue as well as synthetic grafts because it bonds 
within the interstices of the graft matrix (CryoLife, 2008). 
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Chapter 8: Conclusions & Future Recommendations 
 
 The results of this study showed that the electrospun polyurethane can serve as an 
effective scaffold to keep the hMSCs of a biological pacemaker in one centralized location. Not 
only did the polyurethane scaffold successfully inhibit stem cell migration, it proved to be an 
adequate environment for cell viability and gap junction formation. 
 For future work, the team recommends further research regarding the sealing of the 
scaffold around the solid cylinder. Once this problem has been addressed, the team believes that 
the scaffolds can be assembled and used in in vivo studies. Another area of future work also 
includes development of a catheter delivery system. 
 Another potential area of research could be regarding casting of polyurethane with micro-
particles in order to create a controlled pore size. Although the electrospun scaffold was 
successful in preventing migration of the stem cells, there is a lack of a definitive pore size.  
 Mechanical testing regarding the strength of the scaffold needs to be performed in order 
to ensure it can withstand the contractile forces within the heart. Also, in terms of catheter 
implantation, it is necessary to determine if the scaffold can withstand the shear stresses it will be 
subjected to. 
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Appendix 
Appendix A: Completed Pairwise Chart 
 
The two pairwise comparison charts were sent to and filled out by Professor Glenn Gaudette, 
Jacques Guyette, Joseph Dell'Orfano, MD, and Ira S. Cohen M.D., Ph.D. Once returned, the 
design team filled in the corresponding gray boxes; if a white box (located horizontally) had a 
“0”, then the corresponding gray box (located vertically) would receive a “1”. The totals were 
then calculated for each row (see Table 2 for example).   
  
Completed Pair wise Comparison Chart 
PWCC 1st degree functions 
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Degradability    0 0  0  0   0  0 
Biocompatibility  1   1 1 1  1   5 
Immobilization  1  0   0 0 0   1 
Allow gap junction formation  1  0  1    1 1   4 
Myocardium attachment  1  0  1 0     1  3 
Mechanically stable  1  0  1  0 0     2 
Total  5  0  4  1 2  3  15 
 
To calculate the percentage of importance for each function, the averages were first taken for 
each row from each respondent. For example, if the four totals for degradability were 2, 3, 2, and 
0, the average would be: 
2 + 3 + 2 + 0
4
=  1.75 
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Appendix B: Conceptual Designs 
 
Bag – There is a material (mesh, porous polymer, porous metal, porous ceramic) that contains 
the hMSCs in a spherical shape 
 
 
 
 
Pancake Discs 
Four layers of disc attached to the ventricular wall. (Anticoagulant Coating facing ventricle, 
scaffold, cell layer, mesh inhibiting cell migration)       
          
         Anti-coagulant orange) 
(Scaffold(grey)  
 Cells (red)   
 Mesh (green) 
 
 
Three-Layered mesh bag attached to the ventricular wall (blood compatible mesh encompasses 
both cells and attachment scaffold) 
 
  
 
 
 
 
 
 
 
Bi-Layer Pancake Cap 
 
 
 
 
 
 
Flat Mesh Container 
 
 
 
 
 
Open sided patch – attachment dependent hMSCs stay on scaffold, free side to interact with 
myocytes 
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 Appendix C: Candidate Material Analysis 
Nitinol 
The first material that is being considered is nitinol. Nitinol was originally developed by 
the space program Nickel Titanium Naval Ordinance Laboratories (Whittaker et al, 2006). 
Nitinol is a passive shape memory alloy made from 55% Nickel and 45% Titanium (Trepanier et 
al, 2000) that is commonly used in the Biomedical Engineering industry. Some of the most 
frequent applications of nitinol involve vascular stents, orthopedic and orthodontic applications 
(Trepanier et al, 2000) such as arch wires and osteosynthesis plates (Pelton et al, 2000), and it is 
also used devices used in minimally invasive surgery like tissue ablation devices, vena cava 
filters and retrieval baskets (Pelton et al, 2000).  
Nitinol can withstand a maximum strain of up to 8% without permanent deformation 
(Pelton et al, 2000); this attribute is usually referred to as super-elasticity. The material’s super-
elasticity and shape memory properties allow engineers to easily anneal the alloy to a certain 
shape that is then retained. The material can easily be cooled down and deformed in order to 
comply with the engineers’ needs and when later reheated or simply brought back to room 
temperature, the alloy goes back to its annealed shape. This can be very useful when designing 
for implantation or for tool versatility.  
A great attribute exhibited by nitinol that makes it appropriate for blood contacting 
devices, more specifically vascular applications, is the material’s anti-thrombogenic properties 
and corrosion resistance. Extensive research done on the material has demonstrated its 
biocompatibility and leading to its approval by the FDA. The corrosion resistance of nitinol is 
attributed to a stable surface oxide layer that protects the material from its surrounding 
environment and increases biocompatibility. This is achieved by changing nitinol’s chemical 
pathway of oxidation (Trepanier et al, 2000). As part of the design, scratching of the oxide layer 
must be kept at a minimum; especially when considering delivery of the device possibly through 
a catheter. If the oxide layer is disrupted this can affect nitinol’s corrosion resistance properties. 
(Trepanier et al, 2000) 
When testing for biocompatibility, the experiments were designed under the ISO 10993 
standards. The properties of the material that are usually evaluated to asses biocompatibility 
include foreign body reaction, inflammatory response, thrombosis, carcinogenesis, sterilization 
and infection, (InspiredMD Corporation, 2005) as well as mechanical properties like fatigue 
testing. One risk of using biomaterials that contain nickel is the possibility of nickel ions being 
released into the body. It is known that nickel is a potent inflammatory agent in biological tissue 
(Whittaker et al, 2006), and excess release of nickel from the implant can cause harmful 
allergenic, toxic and carcinogenic reactions (Trepanier et al, 2000). Recent studies show that the 
maximum concentration of Ni released by nitinol is 4.1 ppb; and this takes place within the first 
24 hours after implantation. For Ni to reach cytotoxic levels in the human body, it needs to reach 
a concentration of 30ppm (Jia et al, 1999).  
Other experiments have been conducted to further evaluate the biocompatibility of 
nitinol. One concern for our project is fibrotic encapsulation of the biomaterial. If fibrotic 
encapsulation of our scaffold were to occur, then the cells seeded inside of the scaffold will not 
be able to form gap junctions with the cardiomyocytes located at the other side of the membrane. 
A study performed to understand the tissue reactions when nitinol is implanted subcutaneously 
showed that the inflammatory response of the body to the nitinol started 3 days after 
implantation and was minimal. The healing process, which consisted of fibrous encapsulation of 
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the biomaterial, started 1-2 weeks after implantation. (Trepanier et al, 2000) During the initial 
stages of wound healing, the fibrotic encapsulation thickness of nitinol is higher than stainless 
steel. As time goes on, the fibrotic encapsulation thickness of stainless steel increases and 
nitinol’s remains the same. This results in both materials having the same fibrotic encapsulation 
thickness which makes nitinol biocompatible (Ryhanen et al, 1998). Although nitinol is 
considered a biocompatible material and very suitable for biomedical applications there is 
concern of how the fibrotic encapsulation of the material during the healing process will affect 
the outcome of the project. The group needs a material that will limit or completely resist fibrotic 
encapsulation in order to allow gap junction formation between the mesenchymal stem cells and 
the cardiomyocites. Nitinol has great potential due to its mechanical properties, corrosion 
resistance and biocompatibility. Another great characteristic of nitinol is that it is radio opaque. 
This brings the opportunity of tracking the device due to its imaging possibilities (Whittaker et 
al, 2006). 
Due to the material’s hardness and the abrasive nature of its surface, machining parts out 
of nitinol causes a great amount of tool wear. This in turn makes processing nitinol more 
expensive and more time consuming than other materials. A disadvantage of nitinol is that its 
mechanical properties are decreased when welded onto itself or another metal. More detail on 
specific mechanical properties of nitinol can be found on the table at the end of this section. 
Dacron 
The second material that is being evaluated is Dacron, also known as Polyethylene 
terephthalate (PET). Dacron is tough, strong and is fairly easy to shape. It is also easy to join and 
sterilize. This material is composed of tiny woven or knitted fibers that have very high tensile 
strength (Sarkar et al, 2006) and is mainly used in the Biomedical Engineering industry as 
vascular grafts.  
Dacron is usually manufactured into a woven corrugated graft, this is needed in order to 
prevent the material from kinking (Sarkar et al, 2006). This material design allows it to withstand 
the pressures exhibited by high flow blood vessels like the aorta (Sarkar et al, 2006). Since this 
material is used as a vascular graft it means that it is both biocompatible and hemocompatible. 
Dacron is chemically stable and resistant degradation and to toxic or even inflammatory 
byproducts that it might encounter in the blood. The individual fibers are susceptible to slow 
hydrolytic degradation, but the structures that are formed when the fibers are bundled prevent 
this process (Sarkar et al, 2006). Studies suggest that one disadvantage of Dacron is that it is 
prone to infection (Kajiwara et al, 2004). It can be woven or knitted to produce a porous fabric 
(InspiredMD Corporation, 2005), which might be advantageous for the team. Dacron, if 
manufactured with velour construction is believed to facilitate tissue incorporation which may 
work for the team’s advantage when designing for gap junction formations. More detail on the 
material’s mechanical properties can be found on the table below. 
EPTFE 
The next material studied is ePTFE or expanded PTFE. Expanded PTFE was developed 
in 1972. Preferred over Dacron for vascular applications (InspiredMD Corporation, 2005), 
EPTFE is considered the most reliable synthetic material available for vascular grafts (Doble et 
al, 2008). EPTFE was first introduced in the market as a vascular graft in 1975, early studies 
done on the material led to the addition of reinforcing fibers for stability of the graft (Isaka et al, 
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2006). ePTFE grafts currently available in the market are resistant to compression and kinking 
(InspiredMD Corporation, 2005).  
 A study that followed young patients (7-8 years old) showed that the mechanical 
properties of the ePTFE grafts changed between 10 and 52 weeks after implantation. The study 
revealed that the strength of the material was decreased by 50%, the material elongation changed 
by 61% and its crystallinity changed by 3% (Doble et al, 2008). The ultimate tensile strength of 
normal a normal ePTFE vascular graft was 14.57 MPa, after being implanted into the body for a 
few years the ultimate tensile strength of the material decreased to 7.25 MPa (Doble et al, 2008). 
The loss of mechanical strength of ePTFE was also demonstrated by Vanmaele et al., in this 
experiment the results showed to be as drastic as the loss of mechanical strength a week after 
implantation (Isaka et al, 2006). Some researchers attribute the loss of mechanical properties to 
the deposition of lipids and proteins on the graft wall (Doble et al, 2008). In an experiment 
carried out by Geiger, the structure of the ePTFE graft appeared to be inhomogeneous with 
micropores, and compressed and ruptured fibrils. (Geiger,1991) 
So far there are no reported failures due to degradation of the material (Giudiceandrea et 
al, 1998), but this drastic change of ePTFE’s mechanical properties could lead to further 
complications especially if implemented for long term implants.  
 One of the chemical characteristics of this graft is that it is hydrophobic. This quality of 
the material protects the ePTFE graft against bacterial adhesion, resulting in the ability to ward 
off more infections than other synthetic grafts like Dacron (Kajiwara et al,2004). Studies show 
that as blood proteins accumulate in the wall of the graft, this hydrophobicity fades away (Doble 
et al, 2008), and with this, the material’s ability to fight infections. This makes the ePTFE grafts 
more susceptible to infections (Kajiwara et al, 2004). Other problems identified with these types 
of grafts are serum leakage, thrombosis, inflammation mineralization and changes in the 
physiochemical characteristics of the material (Doble et al, 2008).  
 The manufacturing process of ePTFE grafts can be used to control the physical 
dimensions of the material (Isaka et al, 2006). When the graft is not woven or knitted, it can be 
produced into sheets by an extrusion process. This extrusion process results in a porous 
membrane in which the pores can be controlled and produced to a desired size (InspiredMD 
Corporation, 2005) (Isaka et al, 2006). Expanded PTFE membranes have been previously 
manufactured with pores as small as .05 microns (Sarkar et al, 2006). This material is 
advantageous to the team because the pore sizes we are investigating range from 3 -.4 microns. It 
might be possible to produce an ePTFE membrane with the required pore size for our design, 
although the material’s decrease of mechanical strength and biocompatibility after implantation 
are a concern. 
Polyurethane 
The last material investigated was Polyurethane. From the biomaterials that are available 
in the market today, polyurethane is considered the most biocompatible and hemocompatible 
materials. (Zdrahala et al, 1999). The most common brands available in the market for medical 
purposes are Pellethane
TM
, Estane
TM
, Vialon
TM
, Tecoflex
TM
, Corethane
TM
, Bionate
TM
, Biospan
TM
 
and Chronoflex
TM
. (Zdrahala et al, 1999) These materials dominate the field of cardiovascular 
devices (Zdrahala et al, 1999)and are generally used in the biomedical engineering industry to 
make catheters, general purpose tubing, blood bags, heart valves, pacemaker lead wire 
insulation, wound dressings, total artificial hearts and small caliber vascular grafts. (Zdrahala et 
al, 1999)(Boretos et al, 1967) (Alliance for the Polyurethanes Industry, 2001) 
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 Polyurethane’s popularity comes from its great mechanical properties. By modifying 
polyurethane, scientists were able to obtain a material that is durable, resistant to fatigue in 
tensile, compression and shear stresses; a material that is elastic, compliant to surrounding tissue 
and due to attachment of certain proteins even able to encourage healing. (Zdrahala et al, 1999) 
Unlike ePTFE, tests performed on polyurethane’s tensile properties after implantation showed 
that there was no significant reduction of the material’s ultimate tensile stress (Boretos et al, 
1967). The table below shows more detail on the material’s mechanical properties. 
 When evaluating polyurethane’s biocompatibility, tests showed that the material is not 
cytotoxic to cells. (Vinoy et al, 2008). This is very important for the purpose of our project 
because our intension is develop a scaffold in which we can seed cells. Observations made on 
polyurethane vascular grafts after 1 week implantation time showed no thrombus or emboli 
formation. (Boretos et al, 1967) this makes the material appropriate for blood contacting 
applications. MacKay et al showed in 1996 that how modifying polyurethane can give it 
excellent blood compatibility. By adding proteins on the surface of the biomaterial, it is possible 
to give it anticoagulant, infection controlling and tissue suppressant characteristics. Some of 
these modifications also gave polyurethane enhanced wound healing characteristics. (Zdrahala et 
al, 1999). A study conducted by Martinez-Martinez, demonstrated that polyurethane had the 
lowest adhesion and colonization of bacteria when compared to Teflon and silicone latex. 
(Zdrahala et al, 1999) 
 There are many processes that can be used to fabricate medical devices from 
polyurethanes. Among those processes we can find extrusion, molding, casting electrostatic and 
wet spinning of monofilaments, dip coatings and spraying of mandrels. The advantages of these 
manufacturing processes are that they can fabricate membranes with micropores that feel and 
behave like natural tissue. (Zdrahala et al, 1999) 
ChronoFlex Technical Data Sheet 
Properties ASTM Procedure Typical Values 
Hardness (Shore Durometer) ASTM D-2240 80A 55D 75D 
Appearance Visual 
Clear to 
slightly 
cloudy 
Clear to 
slightly 
cloudy 
Clear to slightly 
cloudy 
Ultimate Tensile Strength (psi) ASTM D-638* 5500-6500 6000-7500 7000-8000 
Ultimate Tensile Strain (%) ASTM D-638* 400-490 365-440 255-320 
100% Secant Modulus (psi) ASTM D-638* 770-1250 1850-2200 5300-5700 
300% Secant Modulus (psi) ASTM D-638* 700-1400 1700-2000 2700-3200 
Flexural Strength (psi) ASTM D-790 350 550 10,000 
Flexural Modulus (psi) ASTM D-790 5500 9300 300,000 
Melt Index (g/10 min) 210°C; 
2.17 Kg 
ASTM D-1238 8 5 3 
Vicat Softening Point (°F/°C) ASTM D-1525 160/70 180/80 ------ 
Water Absorption ASTM D-5170 1.2 1.0 0.8 
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Dielectric Strength (volts/Mil) ASTM D-149 360 520 420 
Specific Gravity ASTM D-792 1.2 1.2 1.2 
Coefficient of Friction (Kinetic) ASTM D- 1894 1.5 0.8 0.64 
Abrasion Resistance (% loss at 
1000 cycles) 
ASTM D-1044 0.008 0.035 0.053 
Melt Processing Temp. 
(0°F/0°C) 
  375-430 / 190-220 
Recommended Sterilization 
Method 
  Gamma; E-Beam; ethylene oxide 
Class VI Biocompatibility Test U.S.P. XXII Pass Pass Pass 
* Specimens conditioned for 7 days at room temperature and 50% R.H. 
Physical Properties 
Shore Hardness 80A 55D 65D 
Appearance Slightly cloudy Slightly cloudy Slightly cloudy 
Modulus at 100% 775 1900 5500 
Modulus at 300% 600 ---- ---- 
Tensile Strength (psi) 6600 7500 9000 
Elongation (%) 475 325 250 
 
Information from (http://www.advbiomaterials.com/chronoflex_c_factsheet.html) 
  
78 
 
Appendix D: hMSC Deflection Derivations 
 
 
   
                           
 
 
 
 
 
 
Bending Moment 
The differential equation of the deflection curve of the bent beam is: 
  𝑀 = 𝐸𝐼
𝑑2𝑦
𝑑𝑥2
 
 
From the diagram above, the bending moment is: 
  𝑀 =
𝑤𝐿
2
𝑥 −
𝑤
2
𝑥2 
 
Setting these two equations equal to each other: 
  𝐸𝐼
𝑑2𝑦
𝑑𝑥2
=  
𝑤𝐿
2
𝑥 −
𝑤
2
𝑥2 
 
Integrate: 
  𝐸𝐼
𝑑𝑦
𝑑𝑥
=  
𝑤𝐿
4
𝑥2 −
𝑤
6
𝑥3 +  𝐶1 
 
Boundary condition 1: 
  
𝑑𝑦
𝑑𝑥
= 0   @  𝑥 =
𝐿
2
    (The slope of the deflection is horizontal at =
𝐿
2
 )  
 
Solve for C1: 
  0 =
𝑤𝐿
2
∗
𝐿2
8
 −  
𝑤
2
∗
𝐿3
24
 +  𝐶1 
  𝐶1 =  −
𝑤𝐿3
24
 
Plug in C1: 
  𝐸𝐼
𝑑𝑦
𝑑𝑥
=
𝑤𝐿
4
𝑥2 −
𝑤
6
𝑥3  −  
𝑤𝐿3
24
 
 
Integrate: 
  𝐸𝐼𝑦 =
𝑤𝐿
12
𝑥3 −
𝑤
24
𝑥4  −  
𝑤𝐿3
24
𝑥 +  𝐶2 
 
Boundary Condition 2: 
  y = 0   @  x = 0 
 
Solve for C2 
  0 = C2 
L 
wL 
2 
wL 
2 
E= Young’s Modulus 
I = Moment of Inertia 
w = Force on cell per unit 
length 
L = Length of cell 
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y 
 
The maximum deflection occurs at: 
  𝑥 =
𝐿
2
 
Therefore, 
  𝐸𝐼𝑦𝑚𝑎𝑥 =
𝑤𝐿
12
𝑥3 −
𝑤
24
𝑥4  −  
𝑤𝐿3
24
𝑥  
  𝐸𝐼𝑦𝑚𝑎𝑥 =  −
5𝑤𝐿4
384
 
 
Without regard to the algebraic sign, the maximum deflection at  
𝐿
2
 is: 
  ∆𝑚𝑎𝑥  =
5𝑤𝐿4
384𝐸𝐼
 
 
CALCULATION FOR THE DEFLECTION OF a hMSC 
 
    
                               r = 5μm 
 
Calculation for force on a hMSC (“w”) 
  𝑤 =
𝑃𝐴
𝐿
 
   where A=cross-sectional area of a hMSC 
    𝐴 =  𝜋𝑟2  
  𝑤 =
 𝑃𝐴𝜋𝑟2 
𝐿
    
 
Calculation for a hMSC’s Moment of Inertia (“I”) 
Since a hMSC has an elliptical shape, the moment of inertia for an ellipse will be used. 
 
 
 
 
 
 
 
 
Moment of Inertia for a quarter ellipse: 
  𝐼 =
𝜋𝑎𝑏3
16
 
Since a hMCS will have the shape of a full ellipse, the equation would be: 
  𝐼 =
𝜋𝑎𝑏3
4
 
  𝐼 =
𝜋∗5∗13
4
 𝜇𝑚4 
  𝐼 = 3.93 𝜇𝑚4 
 
Maximum deflection of a hMSC  
  ∆𝑚𝑎𝑥  =
5𝑤𝐿4
384𝐸𝐼
  
E = 126±81 Pa 
P = 5 mmHg = 266.6 Pa 
b 
a 
x 
Cross-Section of a hMSC: 
r 
5.0 μm 
1.0 μm 
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 Appendix E: hMSC Deflection MatLab Syntax 
 
 
For L=3.0 micrometers 
%E=45Pa 
     E=45*(1/((1*10^6)^2)); %N/micrometer^2 
     L=3; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/3; %N/micrometer 
I=(pi*a*(b^3))/4 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 41.6563 micrometers 
  
%E=126Pa 
     E=126*(1/((1*10^6)^2)); %N/micrometer^2 
     L=3; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/3; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 14.88 micrometers 
  
   
%E=207Pa 
     E=207*(1/((1*10^6)^2)); %N/micrometer^2 
     L=3; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/3; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 9.0557 micrometers 
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For L=2.5 micrometers 
%E=45Pa 
     E=45*(1/((1*10^6)^2)); %N/micrometer^2 
     L=2.5; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/2.5; %N/micrometer 
I=(pi*a*(b^3))/4 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 24.11 micrometers 
  
  
  
  
%E=126Pa 
     E=126*(1/((1*10^6)^2)); %N/micrometer^2 
     L=2.5; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/2.5; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 8.61 micrometers 
  
  
  
%E=207Pa 
     E=207*(1/((1*10^6)^2)); %N/micrometer^2 
     L=2.5; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/2.5; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 5.24 micrometers 
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For L=2.0 micrometers 
     %E=45Pa 
     E=45*(1/((1*10^6)^2)); %N/micrometer^2 
     L=2; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/2; %N/micrometer 
I=(pi*a*(b^3))/4 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 12.34 micrometers 
  
  
  
  
%E=126Pa 
     E=126*(1/((1*10^6)^2)); %N/micrometer^2 
     L=2; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/2; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 4.41 micrometers 
  
  
  
%E=207Pa 
     E=207*(1/((1*10^6)^2)); %N/micrometer^2 
     L=2; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/2; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 2.68 micrometers 
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For L=1.5 micrometers 
%E=45Pa 
     E=45*(1/((1*10^6)^2)); %N/micrometer^2 
     L=1.5; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/1.5; %N/micrometer 
I=(pi*a*(b^3))/4 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 5.21 micrometers 
  
  
  
  
%E=126Pa 
     E=126*(1/((1*10^6)^2)); %N/micrometer^2 
     L=1.5; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/1.5; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 1.86 micrometers 
  
  
  
%E=207Pa 
     E=207*(1/((1*10^6)^2)); %N/micrometer^2 
     L=1.5; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/1.5; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 1.13 micrometers 
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For L=1.0 micrometers 
%E=45Pa 
     E=45*(1/((1*10^6)^2)); %N/micrometer^2 
     L=1; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/1; %N/micrometer 
I=(pi*a*(b^3))/4 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 1.54 micrometers 
  
  
  
  
%E=126Pa 
     E=126*(1/((1*10^6)^2)); %N/micrometer^2 
     L=1; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/1; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 0.55 micrometers 
  
  
  
%E=207Pa 
     E=207*(1/((1*10^6)^2)); %N/micrometer^2 
     L=1; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/1; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 0.33 micrometers 
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For L=0.4 micrometers 
%E=45Pa 
     E=45*(1/((1*10^6)^2)); %N/micrometer^2 
     L=0.4; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/0.4; %N/micrometer 
I=(pi*a*(b^3))/4 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 0.0987 micrometers 
  
 
 
 
 
%E=126Pa 
     E=126*(1/((1*10^6)^2)); %N/micrometer^2 
     L=0.4; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/0.4; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 0.0353 micrometers 
  
  
  
%E=207Pa 
     E=207*(1/((1*10^6)^2)); %N/micrometer^2 
     L=0.4; %micrometer 
     a=5;  %micrometer 
     b=1;  %micrometer 
     w=(266.6*(1/((1*10^6)^2))*25*pi)/0.4; %N/micrometer 
I=(pi*a*(b^3))/4; 
%I=3.927 micrometers^4 
d=(5/384)*((w*(L^4))/(E*I))  
%d = 0.0215 micrometers 
  
86 
 
Appendix F: Tables of all Deflection Calculations 
 
Length between Fibers = 3.0 
μm 
Pressure 
(Pa) E (Pa) d (μm) 
133.3 
45 20.78 
126 7.42 
207 4.52 
266.6 
45 41.66 
126 14.88 
207 9.06 
666.6 
45 104.16 
126 37.2 
207 22.64 
799.9 
45 124.98 
126 44.64 
207 27.17 
 
Length between Fibers = 2.0 
μm 
Pressure 
(Pa) E (Pa) d (μm) 
133.3 
45 6.16 
126 2.2 
207 1.34 
266.6 
45 12.34 
126 4.41 
207 2.68 
666.6 
45 30.86 
126 11.02 
207 6.71 
799.9 
45 37.03 
126 13.23 
207 8.05 
 
 
 
 
 
 
Length between Fibers = 2.5 
μm 
Pressure 
(Pa) E (Pa) d (μm) 
133.3 
45 12.03 
126 4.3 
207 2.61 
266.6 
45 24.11 
126 8.61 
207 5.24 
666.6 
45 60.28 
126 21.53 
207 13.1 
799.9 
45 72.33 
126 25.83 
207 15.72 
 
   
 
  
  
  
 
  
  
  
 
  
  
  
 
  
  
  
Length between Fibers = 1.5 
μm 
Pressure 
(Pa) E (Pa) d (μm) 
133.3 
45 2.6 
126 0.93 
207 0.56 
266.6 
45 5.21 
126 1.86 
207 1.13 
666.6 
45 13.02 
126 4.65 
207 2.83 
799.9 
45 15.62 
126 5.58 
207 3.4 
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Length between Fibers = 1.0 
μm 
Pressure 
(Pa) E (Pa) d (μm) 
133.3 
45 0.77 
126 0.27 
207 0.17 
266.6 
45 1.54 
126 0.55 
207 0.33 
666.6 
45 3.86 
126 1.38 
207 0.84 
799.9 
45 4.63 
126 1.65 
207 1.01 
 
 
 
  
Length between Fibers = 0.4 
μm 
Pressure 
(Pa) E (Pa) d (μm) 
133.3 
45 0.0493 
126 0.0176 
207 0.0107 
266.6 
45 0.0987 
126 0.0353 
207 0.0215 
666.6 
45 0.2469 
126 0.0882 
207 0.0537 
799.9 
45 0.2963 
126 0.1058 
207 0.0644 
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